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Abstract. The present study was performed to evaluate the effi-
cacy of circulating cystatin-C as a tumor monitoring biomarker 
at different clinical time points in patients with breast cancer 
over a long-term follow-up period. In addition, the secretory 
rate of circulating cystatin-C from cancer tissue was investi-
gated by comparing the blood and tissue expression levels of 
cystatin-C. Blood samples from healthy volunteers (40 males 
and 40 females) were obtained at yearly health examinations if 
laboratory and imaging abnormalities were not detected. Blood 
samples from 34 patients with breast cancer were obtained at 
205 different time points of clinical progression. Blood levels 
of cystatin-C were measured using ELISA and the tissue levels 
were measured using immunohistochemistry. No age-associ-
ated effect was observed in male and female blood cystatin-C 
levels. The positivity rate was 46% in patients (38/83) and 40% 
in samples collected at different time points (82/205). Blood 
cystatin-C levels were lowest following surgery compared 
with patients with systemic metastasis (P<0.001). The sensi-
tivity, specificity and accuracy rates of ELISA were 53.6, 63.6 
and 53.9%, respectively. The concordance rate between blood 
and tissue expression was 38%. The main reason for discor-
dance between tissue and serum expression of cytostatin-C 
came from low serum positivity in samples showing tissue 
cytostatin-C (3/11, 27%). The specificity between cytostatin‑C 
and CA-125 was highest in tumor absence state. In conclusion, 
elevated blood levels of cystatin-C were observed in 40% 
of breast cancer cases and were tumor-volume dependent. 
However, the concordance rate between tissue and blood was 
quite low, suggesting tumor heterogeneity of cystatin-C expres-
sion or co-acting pathway activation, such as cathepsin D. As 
one-third of breast cancer tissues express cystatin-C without 
cancer antigen 15-3 elevation, cystatin-C may represent a good 
tumor-monitoring marker in breast cancer.
Introduction
Cystatins are a superfamily of cysteine proteinase inhibitors 
found in animals and plants. Cystatin-C, a secreted molecule 
of the cystatin family, is composed of 120 amino acids and 
has a molecular weight of 13,260 Da. Cystatin-C is increased 
in patients with cancer and is suggested to be a better renal 
functional marker than creatinine. In pediatric patients with 
cancer, cystatin-C is a suitable marker for monitoring renal 
function during chemotherapy (1). The importance of the 
accurate assessment of renal function in patients with cancer is 
increasing, and the prediction of the glomerular filtration rate 
with combined evaluation of cystatin-C and creatinine is being 
tested for anticancer agents, such as cisplatin (2). By contrast, 
a low level of cystatin-C is associated with atherosclerosis 
and aortic aneurysm. Additionally, it has been suggested that 
cystatin-C adversely affects metabolic factors, in particular 
abdominal obesity, and thus contributes to the development of 
metabolic syndrome (3).
Cathepsin B is a lysosomal cysteine protease in normal 
tissues, and an important matrix protease in cancers, including 
lung cancer, colon cancer and hepatocellular carcinoma (4). 
Activated cathepsin B is considered to be involved in cancer 
invasion and the destruction of the basement membrane, by 
degrading collagen, laminin and proteoglycans. Cathepsin B 
is regulated by cysteine protease inhibitors, such as stefin A, 
stefin B and cystatin-C. In colorectal cancer, cathepsin B 
expression may contribute to early stage invasion and systemic 
metastasis, without the effect of cystatin-C (5). It has been 
reported that non-malignant colorectal tissues do not express 
cystatin-C, whilst cancer tissues expressed high levels of both 
cystatin-C and cysteine proteinase inhibitors (6). In a previous 
study of esophageal cancer, the intensity of cystatin-C immu-
nostaining in cancer tissue was increased compared with the 
adjacent normal esophageal tissues. In addition, the mRNA 
expression levels of cystatin-C were increased in cancerous 
tissue compared with normal tissue (7). In prostate cancer, a 
significant reduction in the immunohistochemical expression 
of cystatin-C in non-neuroendocrine prostate cancer has been 
reported (8). However, there was strong expression of cystatin-C 
in neuroendocrine-like cells compared with benign prostate 
tissues, suggesting a strong connection between cystatin-C 
expression and neuroendocrine differentiation (8). In breast 
cancer, an imbalance between cathepsin B and cystatin-C 
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expression has been reported in the early stages of cancer 
progression. However, no correlation between cathepsin B 
and cystatin‑C expression levels in histological classification, 
tumor size, lymph node metastasis and hormonal receptor 
status was observed (9). Generally, an increase in the ratio of 
cathepsins to cystatins contributes to tumor invasiveness and 
metastasis (10). However, data are conflicting regarding the 
role of cystatins in cancer invasion and metastasis. High levels 
of cystatin-B and -C predict poor survival of patients with 
colorectal cancer, and increased cystatin-F showed a strong 
correlation with liver metastasis in colorectal cancer (11). 
Additionally, high levels of cystatin-A exhibited a strong 
correlation with tumor size and increased mitotic activity in 
breast cancer (12).
Extracellular levels of stefins and cystatin‑C are also asso-
ciated with cancer progression. In hepatocellular carcinoma, 
increased serum stefin A levels correlated with tumor size and 
number (13), and increased serum cystatin-C levels correlated 
with tumor stage in melanoma (14). In colorectal cancer, a 
correlation between high levels of extracellular cystatin-C and 
poor survival was observed (15). In elderly patients with lung 
cancer, serum cystatin-C levels increased in an age-dependent 
manner between 65 and ≥75 years (16). In serum samples from 
patients with breast cancer, high cystatin-C levels were found 
in larger sized tumors, in older patients and in post-menopausal 
women. Significantly lower levels of cathepsin X and H were 
found in patients with inflammatory breast cancer, and a trend 
was also observed for cathepsin B and cystatin-C (17).
The present study aimed to evaluate circulating cystatin-C 
as a biomarker at different clinical time points in patients with 
breast cancer over a long-term follow-up period. In addition, 
the excretory rate of circulating cystatin-C was investigated by 
comparing the blood and tissue expression levels of cystatin-C. 
To the best of our knowledge, the present study is the first to 
simultaneously assess the expression levels of cystatin-C in 
tissue and serum samples from patients with breast cancer at 
different time points of clinical progress.
Materials and methods
Collection of blood and tissues. Blood samples from healthy 
volunteers (40 males and 40 females) were obtained at Inha 
University Hospital (Incheon, Korea), subsequent to obtaining 
approval if no laboratory and imaging abnormalities were 
observed following check-up in 2003. Blood samples from 
34 female patients with breast cancer were obtained at 
205 different time points of initial diagnosis state, during 
chemotherapy period and off-chemotherapy state between 
January 1999 and January 2003, and stored at ‑80˚C. 
Heparinized vacuum tubes and needles (BD Biosciences, 
Franklin Lakes, NJ, USA) were used to avoid platelet damage 
and venous occlusion, as in clinical sample setting. Following 
surgical excision (29 specimens) or biopsy (23 specimens) 
between January 1992 and December 2002, specimens were 
fixed in 10% formalin and embedded in paraffin. Approval 
for the present study was obtained from the Institutional 
Review Board of Severance Hospital (Seoul, Korea) and 
Inha University Hospital (IRB 4-2009-0256 and 10-617, 
respectively) and samples were used subsequent to obtaining 
consent from volunteers and patients.
Determination of the normal range of serum cystatin‑C. 
Using 40 healthy male and 40 healthy female volunteer 
blood samples, the normal cut-off point of cystatin-C was 
determined. The cut-off point was determined using the 
mean ± 2 standard deviations. The serum cystatin-C level was 
determined as positive when the blood value of the patient was 
higher than the cut-off value (18).
Immunohistochemistry. Sections (4-µm) were stained by 
the horseradish peroxidase (HRP) labeling method. The 
specimens were deparaffinized and immersed in a solution of 
0.1% hydrogen peroxide in methanol to eliminate endogenous 
peroxidase activity. The antibody used was rabbit anti-human 
cystatin-C polyclonal antibody (cat. no. ab68290; Abcam, 
Cambridge, MA, USA) with a 1:2,000 dilution. In total, a 
maximum of 500 cancer cells were counted. Positive staining 
was defined as the presence of cytoplasmic immunoreactivity 
in a minimum of 10% of cancer cells.
ELISA assay. A sandwich ELISA was used to measure 
cystatin-C, cancer antigen (CA) 15-3 and CA125 levels, 
according to the manufacturer's instructions. In brief, murine 
polyclonal antibody specific for cystatin‑C (RD 191009100; 
dilution, 1:400; BioVendor, Brno, Czech Republic), and mono-
clonal antibodies specific for CA15‑3 (cat. no. IS‑F3329; LSBio, 
Seattle, WA, USA) and CA125 (cat. no. CA239T; Calbiotech, 
Inc., El Cajon, CA, USA) were used to coat the 96-well micro-
plates. Each standard and sample was added to the plate and 
incubated for 1 h at room temperature. Following washing to 
remove unbound proteins, enzyme‑linked antibodies specific 
for cystatin-C, CA15-3 and CA125 were added to the wells. 
Absorbance was measured at 450 nm and the detection limit of 
cystatin-C was 0.25 ng/ml. A standard curve was constructed 
by plotting absorbance values vs. the cystatin-C, CA15-3 and 
CA125 concentrations of the standards, and the concentrations 
of the test samples were determined using this standard curve. 
All samples were run in triplicate. The intra- and inter-assay 
variations of cystatin-C were 3.4 and 6.9%, respectively. 
Dilutional linearity was 98%. The upper normal range were 
25 U/ml for CA15-3 and 35 IU/ml for CA125.
Statistical analysis. The statistical analysis and graphing 
were performed using SPSS software, version 20 (IBM Corp., 
Armonk, NY, USA) and GraphPad Prism version 5 (GraphPad 
Software, Inc., La Jolla, CA, USA). The differences between 
the groups were analyzed using one-way analysis of variance 
(Wilcoxon rank-sum test and paired t-test) and the post-hoc 
test was performed by Turkey test. Correlation between 
variables was estimated using the Spearman's rank correlation 
coefficient. P<0.05 was considered to indicate a statistically 
significant difference.
Results
Volunteers and patients with breast cancer. The median 
age of the healthy male and female volunteers was 41 (range, 
25-66 years) and 35 years (range, 21-56 years), respectively. 
A total of 205 samples were obtained from 34 patients with 
breast cancer (median age, 45 years; range, 32-65 years) in 
12 different disease states during long-term follow-up and 
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treatment (Fig. 1). Blood was also obtained prior to surgery 
in 7 patients with prostate cancer and 13 patients with colon 
cancer.
Normal range of cystatin‑C. The mean levels of cystatin-C 
in healthy female and male volunteers were 0.61±0.09 and 
0.73±0.09 mg/l, respectively. The levels were increased in 
men compared with women (P<0.001) and in patients with 
breast cancer compared with female volunteers (P=0.034) 
(Fig. 2). Using a cut-off point of the mean ± 2 standard devia-
tions, the cut-off point was 0.91 mg/l in men and 0.79 mg/l 
in women. There was no evidence of an effect of age in men 
or women (Table I). The positivity rate was 46% in patients 
(38/83) and 40% in samples collected from the different time 
points (82/205; Table II). Blood cystatin-C levels were lowest 
following surgery compared with patients with systemic 
metastasis (P<0.001; Fig. 3). The sensitivity, specificity and 
accuracy rate of the ELISA was 53.6, 63.6 and 53.9%, respec-
tively (Table III). Among the 7 patients with prostate cancer, 
only 1 patient (14.2%) showed cystatin-C positivity by ELISA. 
In the 13 patients with resectable colon cancer, no patients 
exhibited cystatin-C positivity in the blood.
Detection of cystatin‑C by immunohistochemistry in patients 
with breast cancer. Immunohistochemical analysis was 
conducted at 3 different clinical time points (29 specimens 
at diagnosis, 21 specimens following pre-operative 
chemotherapy and 2 specimens at relapse), including 
2 patients with bilateral breast cancer. The positivity rate 
was 41.4% (12/29) at diagnosis, 66.7% (14/21) following 
pre-operative chemotherapy, and 100% (2/2) following 
relapse. In 6 patients it was possible to compare cystatin-C 
expression between pre- and post-chemotherapy samples. 
The concordance rate was 66.7% (Table IV). In the 2 patients 
who relapsed, 1 patient showed cystatin-C expression in 
both the primary and relapsed tumors. The other patient 
showed no expression in the pre- or post-chemotherapy 
samples, while cystatin-C expression was detected in the 
relapsed tumor. In the 2 patients with bilateral breast cancer, 
1 patient exhibited simultaneous cystatin-C expression from 
both breast tumors, while the second showed discordance in 
cystatin-C expression in both breast cancers.
Comparison of paired‑tissue immunohistochemistry and blood 
ELISA positivity. In 16 patients, tissue immunohistochemistry 
and blood ELISA were compared, resulting in a concordance 
rate of 38%. The main reason of discordance between tissue 
and serum expression of cytostatin-C came from low serum 
positivity in samples showing tissue cytostatin-C positivity 
(3/11, 27%). Additionally, the specificity rate was 60%. This 
indicates that in the early stages of breast cancer, the secretion 
Figure 2. Comparison of cystatin-C levels among healthy volunteers and 
cancer patients.
Figure 1. The 12 different time points where blood samples were taken from 34 breast cancer patients. Op, operation; PD, progressive disease; CR, complete 
remission; p, patient number; s, sample number; treat off, no chemotherapy.
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rate of cystatin-C from the tumor mass into the blood is quite 
low (Table V).
Comparison of serum positivity based on the clinical status 
of cancer. The blood cystatin-C levels were then compared 
with the number of metastases from immediate post-opera-
tive samples (no residual tumor), up to 5 tumor metastases. 
The cystatin-C levels were lowest following surgery and 
increased as the number of metastases increased (Fig. 4A). 
In 6 patients, the blood cystatin-C levels from both pre- and 
post-operative samples were compared. Whilst no patients 
showed positivity for cystatin-C expression, the expression 
levels exhibited a reducing trend following surgery (P=0.13; 
Fig. 4B).
Comparison of serum positivity among cystatin‑C, CA15‑3 
and CA125 in breast cancer. In 92 samples with different 
states of systemic metastasis, we simultaneously compared 
Table I. Comparison of blood cystatin-C levels by ages in healthy volunteers.
 Age, years
 -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Sex 21-30 31-40 41-50 51-60 61-70 Total
Male
  Number, n 10 10 13 5 2 40
  Mean ± SD 0.67±0.10 0.76±0.07 0.78±0.09 0.71±0.04 0.66±0.02 0.73±0.09
  Median 0.68 0.77 0.77 0.71 0.66 0.74
Female
  Number, n 12 16 10 2 0 40
  Mean ± SD 0.60±0.09 0.65±0.09 0.55±0.07 0.67±0.03 - 0.61±0.09
  Median 0.61 0.65 0.55 0.67 - 0.61
SD, standard deviation.
Table II. Comparison of blood cystatin-C positivity at 12 different clinical time points.
   Cystatin-C-positive Cystatin-C-positive
  Number of patients, samples, n (%)
Tumor state Patient group patients, n positive/total (%) Positive/total
Presence of tumor  25
  At diagnosis Group C   7 3/7 (43) 3/7 (43)
  During pre-operative chemotherapy Group D   8 8/14 (57) 14/33 (42)
  At first relapse Group F   3 1/7 (14) 1/9 (11)
  During 1st line palliative chemotherapy Group G   5 5/12 (42) 16/32 (50)
  At PD after 1st line chemotherapy Group H   1 6/9 (67) 10/19 (53)
  Treat-off after 1st line chemotherapy Group K   1 2/6 (33) 2/7 (29)
  During 2nd line palliative chemotherapy Group J   0 2/2 (100) 11/11 (100)
  SD after 2nd line chemotherapy Group L   0 0/1 (0) 0/2 (0)
  PD after 2nd line palliative chemotherapy Group M   0 0/0 (0) 0/0 (0)
Absence of tumor    9
  After initial surgery Group B   3 0/3 (0) 0/5 (0)
  After surgery and neoadjuvant chemotherapy Group E   4 6/16 (38) 15/67 (22)
  At CR after 1st line chemotherapy Group I   2 5/6 (83) 10/13 (77)
PD, progressive disease; SD, stable disease; CR, complete remission; treat-off, no chemotherapy.
Table III. Comparison of accuracy of cystatin-C ELISA based 
on tumor status.
 Cystatin-C expression, n (%)
 -----------------------------------------------------------------------------
Tumor status Positive Negative Total, n (%)
Present 22 (31.7) 19 (30.2) 41 (65.1)
Absent 8 (12.7) 14 (22.2) 22 (34.9)
Total  30 (47.6) 33 (52.4) 63 (100.0)
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the cystatin-C, CA15-3 and CA125 levels with the numbers 
of tumor metastases. As the number of metastasis increased, 
CA15-3 (P<0.001), CA125 (P=0.001) and cystatin-C (P=0.035) 
showed dynamic alterations compared to post-operative (no 
tumor) state (Fig. 5). The accuracy rates of cystatin-C, CA15-3 
and CA125 were 50.0, 67.4 and 59.8%, respectively. With 
tumor presence, the concordance rate between cystatin-C 
and CA15-3, and cystatin-C and CA125 were 66.7 and 53.6%, 
respectively. Without tumor presence, the concordance rates 
between cystatin-C and CA15-3, and cystatin-C and CA125 
were 87.0 and 69.6%, respectively (Table VI).
Discussion
Cystatin-C is a non-glycosylated low molecular weight basic 
protein and is the product of a housekeeping gene, CST-3 (19). 
Cystatin-C is constitutively produced by all human nucleated 
cells. Blood cystatin-C levels are independent of age, body 
mass index (20) and sex (15) in healthy individuals (20); 
however, the levels show a weak association with age due to 
Table IV. Comparison of cystatin-C expression by immuno-




Patient Pre-chemotherapy  Post-chemotherapy







Figure 3. Comparison between cystatin-C levels and tumor burden at 
different time points. CR, complete remission.
Table V. Comparison of cystatin-C expression between paired 
tissue (immunohistochemistry) and blood (ELISA).

















Cystatin-C (+)/CA15-3 (+) 23
Cystatin-C (-)/CA15-3 (+) 18
Cystatin-C (+)/CA15-3 (-) 5
Cystatin-C (-)/CA15-3 (-) 23
Cystatin-C (+)/CA125 (+) 16
Cystatin-C (-)/CA125 (+) 20
Cystatin-C (+)/CA125 (-) 12










Cystatin-C (+)/CA15-3 (+) 2
Cystatin-C (-)/CA15-3 (+) 0
Cystatin-C (+)/CA15-3 (-) 3
Cystatin-C (-)/CA15-3 (-) 18
Cystatin-C (+)/CA125 (+) 1
Cystatin-C (-)/CA125 (+) 3
Cystatin-C (+)/CA125 (-) 4
Cystatin-C (-)/CA125 (-) 15
CA, cancer antigen.
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a reduced glomerular filtration rate in elderly individuals (21). 
Finney et al (20) reported no difference in cystatin-C levels 
by age, but the median age of the control group in their study 
was 40 years (range, 19-59 years), while Norlund et al (21) 
reported an age dependency in older individuals. The present 
study tested blood cystatin-C levels in healthy Korean volun-
teers (age range, 21-56 years), which indicated that there was 
no age-dependence in males or females. However, the levels 
were increased in males compared with in females, potentially 
due to a difference in age. The median age of the men was 
41 years (range, 25-66 years) and in the women was 35 years 
(range, 21-56 years). Ohara et al (16) reported age dependence 
in cystatin-C levels in elderly patients with lung cancer aged 
>75 years old compared with those aged <65 years old (16). In 
patients with colon cancer, the cystatin-C levels were 1.4-fold 
increased in all stages of cancer compared with healthy 
individuals (15). In breast cancer, inflammatory cancer type 
and increased tumor size exhibited high expression levels 
of cystatin-C (17). Although the control group was not 
age-matched with the patient group in the present study, patients 
with breast cancer exhibited increased levels of cystatin-C 
compared with healthy volunteers. Due to the availability 
of 205 blood samples from 34 patients with breast cancer at 
12 different clinical time points, the cystatin-C positive rate 
was evaluated at the different time points. This demonstrated 
the tumor mass dependence of cystatin-C level, by the obser-
vation of the lowest serum positivity following surgery, where 
Figure 4. Comparison of cystatin-C levels (A) based on the number of tumor 
metastasis organs and (B) between pre-op and post-op states of primary 
breast cancer. Pre-op, pre-operative; post-op, post-operative.
Figure 5. Comparison of (A) cystatin-C, (B) CA15-3 and (C) CA125 levels 
based on the number of tumor metastasis organs. CA, cancer antigen.
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there is no tumor. However, despite the increased cystatin-C 
levels in patients with cancer, the sensitivity of the blood test 
was only 53.6% and the accuracy was 53.9%, suggesting a low 
secretion capacity from the tumor mass.
Due to the low blood positivity rate, immunohistochemical 
analysis of cystatin-C was conducted to investigate the 
expression levels of cystatin-C in primary breast cancer. The 
expression levels were evaluated at 3 different time points 
(at diagnosis, following pre-operative chemotherapy and at 
relapse), resulting in a positivity rate of 54.0%, which was 
similar to the blood positivity. The positivity rate increased 
from diagnosis to relapse, suggesting an association between 
tumor progression and cystatin-C expression. In addition, 
synchronicity was investigated in 6 paired samples by 
comparing samples taken at diagnosis, before chemotherapy, 
with samples taken following chemotherapy and surgery, 
which resulted in a concordance rate of 66.7%. Two initially 
negative patients exhibited cystatin-C expression following 
chemotherapy. This may be due to tumor heterogeneity from 
the small biopsy specimen or cystatin-C induction subse-
quent to chemotherapy. In previous studies, no differences 
in cystatin-C levels were observed in samples from prior to 
and subsequent to chemotherapy (median age, 57 years) (22), 
while transient increments (20-40%) were detected following 
chemotherapy (within 10 days of chemotherapy) in esophageal 
cancer (median age, 60 years) (23). This requires further 
confirmation through the investigation of an increased number 
of cases.
As the positivity rate was similar in blood and tissue levels, 
tissue expression and blood levels were then compared in 
16 patients. The concordance rate was only 38%, which mostly 
resulted from the low blood positivity (27%) in the tissue posi-
tive cases. This suggests that the blood cystatin-C levels are 
associated with tumor volume; however, secreted cystatin-C 
levels in the blood are quite low in early breast cancer. 
Laurent-Matha et al (24) reported the amount of cystatin-C 
in the extracellular environment is reduced when the cell is 
transfected with cathepsin D. In addition, cathepsin D secreted 
by breast cancer cells extensively cleaved cystatin-C, which 
may reduce the cystatin-C levels in the blood (24).
To investigate the association between tumor volume and 
blood cystatin-C levels, the cystatin-C levels were compared 
with the number of metastases. Cystatin-C was observed to 
be at the lowest levels subsequent to surgery, when the tumor 
had been removed, with the levels increasing as the number of 
metastases increases. As in the immunohistochemical analysis, 
paired comparisons were performed between cystatin-C levels 
prior and subsequent to surgery in 6 patients. Whilst these 
patients did not show serum positivity, the absolute blood levels 
of cystatin-C decreased subsequent to surgery compared with 
the time of diagnosis, suggesting levels are dependent upon the 
tumor volume. Similarly in ovarian cancer, cystatin-C has been 
reported to increase only in patients with cancer, not in healthy 
individuals and patients with benign ovarian disease (25). By 
contrast, cystatin-C levels were low in prostate cancer speci-
mens compared with benign tissues. Wegiel et al (26) observed 
an inverse correlation between the expression of cystatin-C 
and matrix metalloproteinase 2. Similarly, the present study 
did not find any patients with prostate cancer to be cystatin‑C 
positive, suggesting a functional specificity of cystatin-C 
in different types of cancer, due to the presence of different 
co-functioning molecules. Cystatin-C is a TGF-β receptor 
antagonist in addition to a cystatin-C-mediated feedback loop 
that inhibits TGF-β signaling (27). By inhibiting oncogenic 
TGF-β signaling, cystatin-C is effective in preventing breast 
cancer angiogenesis and progression (28).
As a cysteine protease inhibitor, it was reported that 
cystatin-C reduces cancer invasion and metastasis (25). 
Cystatin-C was increased in cancer tissues from ovarian 
cancer, non-small cell lung cancer and in blood samples 
from patients with hepatocellular carcinoma, melanoma, 
breast cancer and colon cancer. By contrast, cystatin-C 
mRNA levels did not change in pancreatic, head and neck 
cancer. Using laser-capture microdissection technology, 
breast cancer cells were reported to show increased expres-
sion levels of cystatin-C, with this correlating with increased 
tumor size (29). However, the increased cystatin-C expression 
relative to cathepsin B (9) and cathepsin D (24) expression 
was reduced. Cathepsin X and H were significantly lower 
in inflammatory breast cancer compared with cystatin-C 
levels (17). This imbalance between cysteine protease and 
proteinase inhibitors may be associated with the ability of 
cancer interstitial tissues to detach, which is important in 
cancer invasion and metastasis (9). High levels of stefin B 
and cystatin-C were associated with poor prognosis, whether 
as a result of primary activation or secondary feedback loop 
activation (15). To investigate whether the elevated levels 
of cystatin-C were associated with tumor mass, we then 
compared dynamic alterations in cystatin-C levels based on 
tumor volume with known tumor markers in breast cancer, 
such as CA15-3 and CA125. Cystatin-C showed a plateau in 
the blood levels as the tumor mass increased, while CA15-3 
showed continuous increases in the blood level with tumor 
mass increases. The concordance rates of cystatin-C and 
CA15-3, cystatin-C and CA125 were low (66.7 and 53.6%) 
when tumors were present compared with when tumors were 
absent (87.0 and 69.6%). This indicates that a minimum of 
one-third of breast cancer showed molecular tumor heteroge-
neity in the expression of cystatin-C and CA15-3.
In conclusion, elevated blood cystatin-C levels were 
detected in 40% of breast cancer cases, with this being tumor 
volume-dependent. However, the concordance rate between 
levels in tissue and blood samples was low, suggesting tumor 
heterogeneity in cystatin-C expression or co-acting pathway 
activation, such as cathepsin D. As one-third of breast 
cancer cases expressed cystatin-C without CA15-3 elevation, 
cystatin-C may represent a good tumor-monitoring marker in 
breast cancer.
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